Dennis E. Marshall - 21 May 2021 Form 4 Insider Report for BIOLARGO, INC. (BLGO)

Reporting relationship: Director
Issuer ticker: BLGO
Reported as of: 21 May 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 May 2021, 20:19:16 UTC
Next SEC filing: 06 Jul 2021
Source filing: View source filing
Reporting owner signature: /s/ John R. Browning, Attorney-in-fact

Key filing fact

Dennis E. Marshall filed Form 4 for BIOLARGO, INC. (BLGO) on 24 May 2021.

Key facts

This page summarizes Dennis E. Marshall's Form 4 filing for BIOLARGO, INC. (BLGO).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 24 May 2021, 20:19.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BLGO transaction Derivative

Option to purchase common stock

Award

Transaction value: $0
Shares: +27,439
Change %: +0.9%
Price: $0.000000
Shares after: 3,070,455
Date: 21 May 2021
Ownership: Direct
Underlying class: Common stock
Underlying amount: 27,439
Exercise price: $0.1800
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This Option was granted to Reporting Person to replace an option to purchase 109,756 shares that had been issued approximately 10 years ago to compensate Reporting Person for services to the Issuer and had recently expired unexercised due to a discrepancy between the original exercise price and the Issuer's current stock price, pursuant to plan adopted by the Issuer's Compensation Committee.

Footnote F2

This amount reflects, in addition to the reported option grant, the expiration of an option to purchase an 109,756 shares of common stock.